1. Home
  2. WENN vs LXRX Comparison

WENN vs LXRX Comparison

Compare WENN & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WENN
  • LXRX
  • Stock Information
  • Founded
  • WENN 2025
  • LXRX 1995
  • Country
  • WENN United States
  • LXRX United States
  • Employees
  • WENN N/A
  • LXRX N/A
  • Industry
  • WENN
  • LXRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • WENN
  • LXRX Health Care
  • Exchange
  • WENN Nasdaq
  • LXRX Nasdaq
  • Market Cap
  • WENN 387.9M
  • LXRX 392.2M
  • IPO Year
  • WENN 2025
  • LXRX 2000
  • Fundamental
  • Price
  • WENN $10.34
  • LXRX $1.23
  • Analyst Decision
  • WENN
  • LXRX Buy
  • Analyst Count
  • WENN 0
  • LXRX 4
  • Target Price
  • WENN N/A
  • LXRX $3.67
  • AVG Volume (30 Days)
  • WENN 194.8K
  • LXRX 5.3M
  • Earning Date
  • WENN 01-01-0001
  • LXRX 07-31-2025
  • Dividend Yield
  • WENN N/A
  • LXRX N/A
  • EPS Growth
  • WENN N/A
  • LXRX N/A
  • EPS
  • WENN N/A
  • LXRX N/A
  • Revenue
  • WENN N/A
  • LXRX $31,213,000.00
  • Revenue This Year
  • WENN N/A
  • LXRX N/A
  • Revenue Next Year
  • WENN N/A
  • LXRX N/A
  • P/E Ratio
  • WENN N/A
  • LXRX N/A
  • Revenue Growth
  • WENN N/A
  • LXRX 1251.21
  • 52 Week Low
  • WENN $10.30
  • LXRX $0.28
  • 52 Week High
  • WENN $11.91
  • LXRX $2.45
  • Technical
  • Relative Strength Index (RSI)
  • WENN N/A
  • LXRX 65.43
  • Support Level
  • WENN N/A
  • LXRX $1.14
  • Resistance Level
  • WENN N/A
  • LXRX $1.43
  • Average True Range (ATR)
  • WENN 0.00
  • LXRX 0.12
  • MACD
  • WENN 0.00
  • LXRX 0.03
  • Stochastic Oscillator
  • WENN 0.00
  • LXRX 68.25

About WENN Wen Acquisition Corp Class A Ordinary Shares

Wen Acquisition Corp is a blank check company.

About LXRX Lexicon Pharmaceuticals Inc.

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.

Share on Social Networks: